Pfizer to cease operation at two plants in Maharashtra & Tamil Nadu
Category: #health  By Shikha Sinha  Date: 2019-01-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer to cease operation at two plants in Maharashtra & Tamil Nadu

In what may seem to be a response against failing product demand, the U.S. drug manufacturer Pfizer announced that it will be closing its two manufacturing plants in India. The plants, reportedly, manufactured generic injectable such as the penicillin.

According to sources familiar with the matter, the closure of the two plants situated in the states of Maharashtra and Tamil Nadu will affect the employment scenario of more than 1,700 people. These two factories, for the record, employs roughly 6% of Pfizer’s global employees.

Pfizer said that it has conducted a thorough research of the sites and has evaluated that the factories has been incurring significant long-term losses in terms of product demand, and concluded that manufacturing at these sits will not be financially viable for the company.

Reportedly, the U.S. based pharma major acquired the factories in 2015 as a part of its USD 15 billion purchase of Hospira. It aimed to boost the company’s current portfolio of generic injectable drugs & copies of biotech related medicines

As reported by Reuters, Pfizer is also shutting down a Hospira R&D lab located in Taramani, Chennai, however, the closing of this lab was not related to the two manufacturing plants. A spokesperson further revealed that nearly 150 employees were reported of the shutdown, in the fourth quarter.

Sources cite that Pfizer’s Chennai-based manufacturing plant manufactured generic injectable penicillin, penems, and cephalosporin, while the Aurangabad-based unit supplied the Chennai plant with specific products. It has been reported that both the plants in India did not manufacture products for the domestic market.

According reliable reports, the Aurangabad site currently employs over 700 people, while the Chennai unit employs around 1000 people.

Pfizer, however said that the exact time of the exit is not yet be planned and further revealed that it will be expanding operations in its Visakhapatnam-based facility that will cater to export markets including U.S. as well as Canada.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...